Is 'Buy The Dip' Working Again?

Episode Summary:

• Earnings from LEN, AZO
• UBER gives updated guidance

Guests:

Frank Holmes, Executive Chairman, Hive Blockchain (HIVE) CEO and Chief Investment Officer of U.S. Global Investors

Jay Young, President and CEO, King Operation Corporation

BENZINGA CANNABIS CAPITAL CONFERENCE

The premier gathering of cannabis entrepreneurs and investors in North America returns for a 2-Day Hybrid Event on October 14-15.

Speakers will include $SNDL and other major Cannabis Companies, for more information visit https://www.benzinga.com/events/cannabis/

MEET THE HOSTS:

Dennis Dick

Twitter: https://twitter.com/TripleDTrader

Mitch Hoch

Twitter: https://twitter.com/STORYInvestors

Joel Elconin

Twitter: https://twitter.com/Spus

https://www.premarketprep.com/

Disclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.

Subscribe to all Benzinga Podcasts at https://www.benzinga.com/podcasts

Unedited Transcript

All right. All right. What's going on, everybody having. Whew. We are back at it, wine and down the end of the week, another dreary to Detroit day here behind me. I hope everybody's got a little bit more sunshine than we do. It's also very cold. I'm now wearing a light jacket in the morning, but what's going on guys.

Market is ripping again. We are back to where we were before that Monday sell off, you buy the dippers out there. All of you by the dippers. I was not wanting. Congratulations to you. Round of applause, pat yourself on the back, you won a game. Uh, you know, I'm going to go ahead. Let's just look at this, this chart aspire really quick for a second, and we're going to zoom it out to a year and then we'll go to five years.

Uh here's the one year chart is by, by the day. Tried and true. Uh, here's a two-year charter spy by the dip tried and true five years. All right. I guess at the, by the dippers, just always seem to win this one. Uh, but what's going on guys? This is the power hour. This is the trade idea show. That's why we spend this time together every single day.

So if we are not delivering on ideas, call us out. You are empowered to do that in the chat. We're going to get rocking and rolling. Uh, first op we're bringing in Daniel from Curzio reading. Good. Good, good friend to Frank over there. Uh, and Daniel's going to be dropping some ideas on us. He's gonna be talking about the China situation a little bit, I believe.

Uh, and then we, we have three public company CEO interviews today. Jam pack guys. Okay. Three public company's CEO interviews. A lot of them may be stocks that you're not familiar with. I'll give you the tickers there. S T a B N G T F and S O V O. Uh, so, so again, S T a B N G T F S O V O a, but without further ado guys, uh, let's go ahead and bring Daniel from Curzio research in there.

And when you, if you have takers, drop them in the chat, uh, I see, et cetera, ETCs already go and he's got his affirm on there. He's got his hymns on there. Um, and, and, yeah, let's get these in here. Solar ops. We're talking about the cannabis. I am not in any of the cannabis stocks now, but, but, but maybe I ought to be, but let's ask Daniel, Daniel, are you in any of the cannabis names?

Um, not right now. No, but, uh, they've been coming across the headlines a lot. And first of all, thanks, thanks for having me great to be here. Um, but if I were to look at something in full disclosure, I don't have it and I've been kicking myself, but , uh, if you want to pull that up, there are basically a roll-up company that does a medical marijuana and the facilities that they're going to use to produce and grow and distribute.

And that's char has been absolutely beautiful from an investor standpoint. Five-year chart. Yep. And, uh, those guys, uh, I believe it's wall street guys that just got together and man, they they've just been knocking it out of the park. So that's the one that I would look at first, other than the big names Tilray and those et cetera.

But man, a friend of mine gave me that under a hundred and I just kept thinking, all right, I'll wait and wait and wait. And, uh, that's, that's frustrating, but that's investing that's okay. Uh, and, and Daniel, but before we hop into it, uh, give me a little bit of your background. Tell us, tell us about your trading investing career.

Um, and then let's dive into some time. Absolutely. So I joined a Frank Curzio here at Curzio research. Uh, coming up on four years. It'll be four years this October next month. And my background before that was, I started in the brokerage business as a financial advisor, uh, had series seven and 66. Then didn't enjoy that.

I like the research side, but not the front office standpoint. They believer in savings and investing. And on the saving side, I'm big into whole life insurance as a, as a wealth management tool. I know that raises a lot of red flags and always gets a good conversation started, but that's for another time, I can argue that until I'm blue in the face.

And, uh, then when I was listening to Frank's podcast and following him through his career, and when he said that he was starting his own shop and wanted an analyst, I threw my hat in the ring and here we are going on four years. Uh, and give it, give us the short insurance pitch. The short insurance pitch is if you're disciplined enough to say, if you compare a whole life insurance policy to a bank account, there's no other product out there that is quote unquote as safe and reliable.

And it gives you the opportunity to earn interest as you use your money. And there's a big difference between the interest you earn and the interest you pay with the flexibility on that. It's a fantastic wealth building opportunity over the long term. It's not a trading deal. Uh, if you're, if you're old right now and I don't mean to be rude about that, uh, that's what, you know, everybody thinks they're too old for everything these days, but, uh, if you're anywhere under, I'd say 50, you ought to really give it a look and most policies are set up.

In favor of the insurance company, meaning higher commissions, and you can split those premiums up and infinite banking process. If you Google that, you'll, you'll see a lot of good stuff. Uh, infinite banking by, uh, Nelson Nash. I believe I'll tell my head as a great book to dig into. All right, there we go.

And if anybody has a question about the insurance side, dropped them. And I'll pass it along to Daniel, but all right. Let, let, let, let's get back to the stock side. What what's on your radar right now? What are you thinking about? We, you, you gave us a cannabis name to look at already, but, but what else?

Yeah. And that was driven by, uh, you know, if you, you guys are all market junkies. So as you're looking at headlines and everything, uh, the biggest lesson that I'm learning and, you know, I don't have a crystal ball or anything, but you gotta be able to decipher. News to act on and what to ignore. And when you just, when your market junkies and you see a lot of things coming across your desk or your eyes, uh, in my opinion, headlines around pot stocks kind of went away and now they're coming back and I say, they're coming back over the last month, at least in my opinion.

So, uh, and that's driven politically, uh, there's a lot of headlines about, um, there's a group of. I think there's a bill in the house or the Senate. I'm sorry, I don't, I'm on the fence there about protecting banks that do business with, uh, pot stocks, because that's a big red flag right now. Cause you still have this illegal NIS at a certain level.

I mean, it's kind of scary to think about, Hey, the feds can basically go in and shut anything down, but we're not going to. So we're in this process of, Hey, this is a law, but we're going to ignore that. Uh, we see a lot of that with politicians on both sides of the aisle. So that's not anything new. That's, you know, I look through the world from a political and economic lens.

Uh, I think everybody should do that because it literally affects everything in our lives, in reality, as consumers and individuals. Okay. Alright. And I'll, I'll draw, I'll throw mine in the ring too. I'm going to throw in the, the one that everybody thinks about, but till Ray, uh, Erwin Simon, CEO of Tilray founder of Hain, celestial, good friend of Benzinga.

Um, I, I, he he's, I followed his career for quite a while and he's just such an incredible operator. Um, and, and so if I had to pick one, I'm picking the track record of, of, of his, on the management side and that's where Tilray would be my plate. And that's great because you want to focus on individuals. I mean, when you, when you don't have an investment that you can control, so it's not close to the vest you want to invest in management teams.

Um, Frank talks a lot about that with, especially in the resource sector, you want proven management teams, you want skin in the game. So if that gentleman and you know him like that, that that's a, that's a check mark on the, on the good side for the teacher. Yeah, absolutely. All right. Well, what else is on your mind?

You know, Yeah, we'll go from a boring to exciting. So low-hanging fruit. Uh, Intel has dropped the ball for a number of years. They've let you know, their lunch has been eaten by their competitors. They have a new CEO and I'm going to butcher this, but pat gins learner, and he just took over in February of this year.

And I think that this is a situation where you can buy it and forget about it. I have a little bit of a full disclosure. You earn a decent yield. And I think that as there's more volatility in the markets, and if you see this transition from growth to value, like everybody's warning about or volatility, you're going to go into hard brand names, solid brand names with good balance sheets.

And they. Just have to quit screwing up all the time, in my opinion, to get a higher price, uh, the new CEO's got big ambitions. That's what I like to see either. They're going to invest a lot in fab centers, uh, semiconductor buildings over the next several years. And that's a huge secular bull market.

That's not going away anytime soon. So Intel, if it's not exciting, But I do think that that's the lowest hanging fruit out there on a, on one of the big, yeah. And looking at some of the multiples really quick. I mean, it seems like a pretty cheap stock. So we're looking at a forward PE ratio of 12. Um, I don't have the S and P 500 handy, average handy off the top of my head.

Right. At least in the twenties, uh, and then a price to sales, a 2.8 versus that one I know S and P average is, is a little bit over four. So, so it definitely seems like a relatively cheap stock. Yeah. And you can argue, I mean, the, the lower PE uh, forward P against its peers is warranted right now, because again, they've been dropping the ball so many times, so this new CEO starts to get some momentum, starts to prove that they can show results.

I think that you can see that P rice faster than the actual results in reality. Markets are always forward-looking and that's exciting. That can be good or bad, but again, you get a few, uh, you get a few check marks on this guy's side, and I think it could just take off and easily be, you know, 20, 25% and then kind of find that new normal and hang out there for awhile.

And again, you get paid to wait and are you really worried about Intel going bankrupt? I'm not, but you know, that's a good, that's a good hiding spot. And I don't think it's going to be dead money going from. Yeah. And check this out guys. I, I just, I just want it up an income statement really quickly. Uh, you know, th this, this top number that we have here that I'm trying to highlight, uh, th th this is quarterly revenue, and I mean, we're looking at like five quarters in a row with.

Literally no growth. Um, you know, we, we zoom it out to annual revenue and we're getting a little bit of growth there. Um, but, but not, not crazy exciting. I think that's what Daniel's referring to. Yep. Absolutely. All right. All right. What else you said you're gonna start pouring and taking. That's boring. So a upstart U P S T is the taker and a quick, uh, are you familiar with this company at all?

I am going to Lockton. Who's also a good friend of Benzing as is very, very hot on this stock. A couple of times to us it's been absolutely going crazy lately and quick, a rabbit trail here. You guys need to be going through 13 F filings. Uh, there's free websites out there and that's just great use the power of the internet.

We've never lived in a better time where guys like me on 35 can take advantage of, I mean, the amount of resource we have or the amount of information we have for free right now over the internet. It's just a huge step forward and it's just blind, dumb luck that we get to live in this period. None of us picked when we got to be born in order to get some of this information at all, you'd have to go to libraries, different things.

So take advantage of there's 13 S I was going through those, uh, Dan Loeb of third point. Somebody I really respect and you know, like to listen to anything he writes or says and read anything he writes. So I just saw this in a filing and I just went through ticker symbols. Um, they're in a major growth platform where the banking and financial services are using a lot of AI.

They have been for some time, but it's getting a lot of capital to flow into that space right now. So they do personal loans, consumer loans, and they basically go in and show banks, Hey, we can show you how to make more loans with a. Risk tolerance and a lower default rate. And why wouldn't you pursue that or look into that if you're a bank and that's a scalable business with all the loans and trillions of dollars out there.

And as you can tell, I would wait for a pullback. This is definitely a momentum stock. Uh, we were just talking about, uh, PEs with, uh, Intel. I don't know what it is off the top of my head, but it's gotta be through the roof on. All right. And, and I want to throw this one out to the chat to, uh, is anybody in this Docker to anybody get into the stock from the show?

Because when we first talked about it, it was in the seventies somewhere. I, this is the first time I've looked at it in a wild scene, three 40. I, I clearly missed the boat. Uh, but, but I'm curious if anybody out there caught the rip in this one. And so, so Daniel, I like, I like what you're picking up on it that you want to wait for for some of that pullback and.

Let's let the momentum co come to a close, um, with the model like you're saying is so good. It's so reoccurring too, right. Is once a bank becomes dependent on upstart for, for lending and being like a core part of that engine is as to how they're pricing and deciding who to lend to. I would imagine that that's impossible, damn near impossible for these banks to rip out of their operations.

Yeah, absolutely. It's, it's a sticky product and it's scalable. So as an investor, that's a great thing to have. So, you know, be, be prepared for volatility. Um, I, quick story. I told my dad about this around $95 a share, and I said I was buying it and I didn't. And he did, and I wasn't lying to him and it went.

50 or whatever. And now look at where it is. He didn't sell it. So he's very happy. But of course I was kicking myself. I think I bought a gold stock or whatever, which I'm still down on. Uh, but I said, Hey, you need to buy this. I should buy this, but I'm going over here. And he did. So that's good. All right guys, and check out the quarterly revenue on this one.

We're looking at four quarters of data right here on upstart again, sticker U P S T. We went from $51 million of sales to $194 million of. In four quarters. That's I don't know if there's other public company that operates at this scale that, that that's had that kind of growth. I mean, that's, that would be, if somebody out there wants to go run a quick stock screen, so set maybe market cap threshold somewhere, uh, or, or may set a revenue threshold outlet, like 50, a hundred million dollars and see if any other companies have this kind of growth.

I, I would imagine that that there's not one. All right. So, so you're making it more exciting. Do you have a third one for us? Yeah. Along the same lines with the financial platform online platform, a sofa Jeffrey's just came out with initiation yesterday. I've been watching this. It's been volatile as well, and they put a PR $25 price tag it, price target on.

If I, uh, if I remember correctly, which is damn near 50% upside from current levels. Well, depending on what it's doing right now today, but. You have a lot of money flowing into this space. It just makes sense from a standpoint and hell their name is on that, a beautiful new, however, billion dollars. It took to build that a football stadium out in California.

Yeah. That, that, that, that was definitely an expensive sponsorship. I guarantee that. Yeah, I see, I see I'm using my trusty Benzinga pro here, looking at the recent analyst price targets. Uh, you know, I see the Jeffries yesterday that you mentioned at 25 Mizuho out there at 20. And then the, the low of the street credit Suisse came out about two weeks ago at 16 and a half.

Um, and, and, and so, so BA basically, uh, is, is the thesis on this one? Daniel it's it's right. Space, right stock within that space. Yeah, absolutely. It's just, it's more of a momentum play. Uh, I liked the idea in general, but it's just when you have massive amounts of money flowing into that and strong brand types, uh, those are great for trading opportunities and then they can turn into long-term holdings.

Okay. Yeah. And I'm zooming into a five day chart right now. So it's what we're looking at. I believe our five minute candles, let me get a, from a 10 minute candles, five day chart. Um, and, and we, we definitely see that rip higher with the market yesterday, uh, in, in tack down another 2% so far today. So, so, and let me throw this one out here, but I definitely see this symbol come up if anybody has long.

So if I take her S O F I give me the one in the chat, if not give me the two, I want to get a sense of where the crowd is at on the. Uh, I I'm not in so far, but I do own a couple of the online brokerages. Um, one that I'm getting hammered in right now, uh, I've trimmed the position, but still have a little bit of a position in his tiger.

Ticker T I G R a. It's like, like the Robin hood of China, Singapore, et cetera. Um, wow. We have a lot of Sophie owners in the chat check this out. Okay. So a lot of people who like sofa, I can get behind that. All right. Okay. All right. Daniel, anything else for us before we gotta hop? Uh, yeah, if you want to have a fun, uh, political pick a Smith and Wesson brands, uh, they're a pure play on fire symbol on that one.

S WPI. Thank you. You can see, we impressed. So that was the first you're you're on stock number four, and I knew the first three. Okay. There you go. All right. SWB. So that massive spike there was after an earnings release, uh, they've recently, uh, I think right around the first of this month, September, they did their quarterly earnings, but that massive spike there, that what you can see on the chart is they blew out the numbers on the earnings release.

And then it looks like the Reddit crowd got involved because look at that massive sky high, I mean, that thing just went parabolic for several trading days. Uh, this is a pure play on firearm. I know that's a touchy subject politically, but when you look at the numbers, the FBI background checks and things are falling year over year because of the strong, strong comps that they're compared to during the riots and the 2020 and all that kind of thing.

But 50% of new gun buyers are women. Um, everybody I'm a small town guy. I grew up around firearms. So I'm biased as everybody else is, but I'm biased towards them. This is a company with no debt. They are. In a position to continue raising their dividend. Uh, it's not impressive. It's not a high yielding thing, but they are buying back stock as well.

And you have a solid company with an amazing brand name and you have a product that people are, um, you know, it's, they have a huge demand for their products right now, their backlogs or their inventories about an eight weeks, which is kind of where they want to management. They're going to have issues along with everybody else with supply chains.

When you get a great business in a fantastic financial shape and a well-known brand, um, that's, that's a good one right there. So, and it's got a decent short interest. So that, that spike that you see on the chart that could easily happen again. Alright. I like it. It's interesting. I have, uh, let me throw this edgy Daniel, then we're going to have to hop in a minute here, but here here's my take on the gun stocks is I feel like literally always, or at least.

Once a year for the last 10 years, there's like a shortage. And like, there just becomes this narrative, all of a sudden that there's a shortage on guns or there's a shortage on ammunition. And then just a ton of energy pops into these stocks. And you know what I mean? It's it, it just seems like, uh, like, I don't know, like I'm sick, I'm bored of the narrative.

Yeah, it does. I mean, and you're right. That does happen. I will tell you the biggest risk I see. This is, and why I think you have some short interest is you have such a political movement and like your major funds and investment companies like BlackRock and those, they have, they kind of shun these kinds of stocks.

So you have a great business. You have high profit margins, but what's going to be. The big guys from flowing more money into these stocks is political reasons. That's your biggest risk in my opinion, but yeah, you're right. They, they get hot. They could be used as tradable securities. So that would work out for your listeners, but I wouldn't feel bad about buying and holding this either, but yeah, if you want to trade the pops and, uh, you know, sell on the rips and buy on the dips, that's a great idea.

Right? Alrighty, Danielle, I appreciate you hopping on with us. How can folks stay in touch? Where should they go? What should they check out? Yeah. Uh, my email isDaniel@curzioresearch.com. Be sure to check out Curzio research.com and our wall street unplugged podcast that we now do over Tuesday, Wednesdays and Thursdays every single week.

Alrighty. There it is. Thank you for joining us, sir, and dropping the ideas. All right. All right, guys. How was that? I see recurring theme of the chat and talk about Viacom. We will get the via, comes to your V I a C, but, but without further ado, w w we're we're going to keep the show rolling. Uh, we, we've got a nice slate of guests coming in for us today.

Uh, first up CEO said, taro, biopharma, Mike Handley. I'm going to go ahead and let's bring Mike onto the. How are you doing today, sir? Thanks for that. Absolutely. Uh, and, and everyone, the stock symbol is ticker. S T a B said Sandy tango alpha Bravo, Bravo. Um, long week. Um, but, but, but my, my, I I'm one for, for a good stock symbol.

You know, if, if, if a, if a company has a good ticker symbol that like automatically notches it up in my book, so maybe we could just start there for a second. Uh, why. Yeah. Interesting question though. Thanks for having me again. Yeah. Stab is a Sitara biopharma, obviously ticker symbols are a little hit and miss.

Um, we were going for sta T but uh, stab is memorable. Um, and it also goes with our tagline, take a stab at stopping. Right. So, okay. We think it's more memorable than most taglines. Absolutely. No, that's great. I love it. It's like some of the ETF funds, right. I read out to them to I'm like, I don't know how you guys pick the ticker symbols, but if there's like a group or like, you know, something you survey include me in there, I haven't gotten any responses, but I love the memorable ticker symbol for sure.

Absolutely. And, and, and Mike T taking a step back from the ticker symbol to the company. Uh, could you just give us a little bit of an overview on Satara for anybody out there who might not know. Yes, the terrorist, a, a company that just became public, uh, July 27th through a combination merger with Cleveland Biolabs, which was a NASDAQ listed company.

I've been running a state Tara since April of last year. Um, we, uh, talked to Cleveland Biolabs synergistic platforms. So we're most looking at immunotherapies and, uh, it looked like a good combination of two companies. So we combined the two companies officially July 26. Or July 27th. Yeah. And I've been trading since then, and I've been working with circuits and getting visibility for our pipeline and we're about ready to initiate some Wade stage drug programs, uh, that we're really excited about that should help patients and deliver some new immunotherapies to the field.

Excellent. And Mike, you, you, you, you mentioned, I think it was April, 2020, that, that, that, that you joined the company, is that accurate or that you've been running it. Yeah, I've been running it since April, 2020. We've done two acquisitions, um, raised or secured over a hundred million dollars in gone public.

So it's been a busy what? 17 months. Yeah, no kidding. So, so, so, uh, the, the next question I have is, uh, is on background and, and I, I sort of have two pieces of it. Um, and, and you can pick the answer one, one, or both, uh, but, but either what, what was the impetus for the company? Or can you talk a little bit about your career prior, prior to.

Yeah. Yeah, I'll answer both. So I've been in front of biotech for 24 years of running companies for the last 15 years. I'm very interested in the biotech space. Immunotherapy space started off at Amgen Genentech, which are the two big giants and biotech, of course, Genentech bought by Roche now, but Amgen still, uh, independent, uh, took over 17 products to market.

You know, raise close to half a billion dollars and, uh, Brandon's is the terror. Like I said, April last year, they had a very interesting portfolio and uh, thought, um, this would be a great public company, a great opportunity to get some drugs, to some much needed patients, um, that don't have any other alternatives that are.

Uh, so very excited about our platform, multiple shots on goal. We've got a great story and it resonates well with the street, from our interactions and our non-deal roadshow we've been doing. So we're very excited, better than current position. Okay. And I'll, I'll pick up on that roadshow comment that you made, you know, and w when you're going out to wall street and you're talking about the company, uh, you know, what, what aspect of the business is, is getting investors most.

Yeah. Great question. So if you follow the biotech sector, we've seen immunotherapies just exploded in the past five years, I'll use two examples, Humira, which is a TNFL Footlocker sells about $19 billion a year. What's number one, uh, drug selling in us. And I think the world, and then you look at Keytruda.

Merck's drug is a PD, one PDL, one inhibitor. It sells at 13 billion. It's also. Um, our approach to immunotherapies is a little bit different than what big pharma is doing. Those particular drugs suppress the immune system, uh, as in Humira. And they do that, um, to account for, um, uh, Crohn's disease, IVG rheumatory arthritis, and then the cancer drugs take the brakes off your immune system.

So in effect, our narrative to wall street is the current immune therapies out there or. And they're generating a lot of cashflow and they're helping patients, but they also come with a large amount of side effects because you're suppressing the immune system. Um, in the one case with the Humira and other TNF, alpha blockers and the other cancer cases, you're increasing the probability of hyper inflammation in those patients.

And that's been a cause and a concern and a warning for Keytruda, both great drugs, uh, both help patients, but we think there's a better way of doing immunotherapies. And that's what we're telling the street. And they're gravitating. Okay. And can you talk to us a little bit about him? Question in specifically the integration stuff.

Yeah, I'm close was the second company we acquired. Um, they're a research driven company with, uh, cashflows and, uh, we're in the process right now of integrating them into our R and D platform. And they're working on our second gen, uh, immunotherapies. And we've got a couple of, uh, potential interesting candidates we're working through, but the inquest simply adds to.

And, uh, we're building, I think one of the more interesting and the largest tool, like reception pipelines, um, in the U S if not the world, and that provides us with, again, a lot of shots on goal and a lot of ways to help patients. Okay. And I guess maybe taking a, a step back or a step higher than, than, than inquest specifically.

Uh, but, but how do you see M and a fitting into the company's roadmap and why have you made the choice that, Hey, that that's the route that we're going to pursue to really grow. Yeah, I'm a firm believer the, uh, Biven bill, right. It's a lot of companies out there that have interesting technologies or platforms that would take me, you know, months to years to replicate the same thing and a much higher dilution to our shareholders.

So, um, being opportunistic, looking at companies with the us. Uh, or complimentary or technologies that are complimentary. Um, we'll definitely use our public stock as currency. And like I said, we're well capitalized and we'll be opportunistic about what we go out and acquire, but it's definitely in the mold of our strategy going forward.

So look at M and a, and be opportunistic about increasing our pipeline, both depths. Okay. And Mike, let, let, let me ask you one more question. And this one is always a tough one. Uh, but, but if you had to name one, one thing that you're most excited about, so somewhere on the roadmap, what, what would that one idea.

Yeah, great question. Everybody asks me, um, obviously cancer therapies are near and dear to everybody's heart. Everybody knows a relative or friend that has cancer, and we've got some very good cancer therapies for developing an adjunctive treatment. Um, but probably the drug program I'm most excited about is our Crohn's programs.

So what we've seen in phase two data is, uh, double the rate of remission in patients who take a once a day world. So current standard of character, marrow, injectable, biologic, um, you get a remission rate of in the low thirties. Um, our what our data, what we've seen is about a 67% remission rate, four weeks, once a day dosing, that is very compelling.

And then the other thing I'm really excited about Crohn's is currently for pediatric Crohn's patients. There's nothing out there that, uh, Works. Well, all of that is black box warning. And as kids develop their immune system, it's really hard for them to be on these biologics, like Humira, Stelara, and Remicade.

So we're running a phase three pediatric study that should kick off by the end of the year, um, in, uh, pediatric Crohn's patients. And we believe this will be a viable alternative to all the kids out there suffering from Crohn's disease. Awesome. Mike, I appreciate you taking the time to come on with us today.

CEO said Tara, a ticker S T a B. And as I said, I do love that symbol and I love the memorability of it. If that's even a word, digging a stab at cancer. Awesome. Yeah. Appreciate it. Thanks for, thanks for your time. Have a good day. Absolutely. You as well. All right. All right, producer, Amy, what do you think.

Love it love the company. Love the ticker. Great to have Mike on. Um, but Luke, we have an absolutely packed power hour show. Today. We brought on Daniel from wall street and unplug. We brought on my from Sitara buyout. Now it is time to bring on Sean C Sean folks and CEO of night food. Um, so without further ado, oh wait, wait, wait.

Celsius is a hundred bucks. No way. Wait, did we ever get the video of Jonah shock? He said, he said he was going to shut you down. He did it leap and you're sleeping on Celsius. Sorry. Um, yeah. And then you also saw the news that Jonah said a Celsius is sending us some, some drinks to Florida for the conference.

Yeah. Guys, if you want to come hang out with me and producer a B in journal up them and put the link in the chat, come say, hi, it's going to be about. That's really the only thing that's keeping me going at this point. So there you go. It will be a good time. Um, all right, Luke. Well, without further ado, I'm going to go ahead and bring Sean folks in on the show.

Sean CEO of night food. Thank you for joining us on the Benzinga power hour. How are you doing on this beautiful Thursday? Great. My pleasure. Happy to be here. Great to have you, um, before we get started, do you mind just giving some, uh, background on the company for maybe some of our audience that may not be familiar?

Sure. So across the country, On any given night, you've got over a hundred million people that are snacking in between dinner and bed. Uh, the most popular choices tend to be things that are loaded with excess fat, excess sugar, excess calories. Cause that's what we're hard wired to create. So you've got all these snacks being consumed, and they're not only unhealthy, but they're actually disruptive to sleep.

When you eat the wrong things before bed, it can impair your sleep quality. So knowing that so many people are snacking at night on a regular basis, what night food does is we deliver healthier snack options that are specifically formulated to satisfy those nighttime cravings, but do it in a better, healthier, and more sleep friendly.

There's plenty of companies out there over the last 10 or 15 years that have launched and had a lot of success with better for you snacks, which are generally healthier in terms of, you know, protein content or sugar content or caloric content, but only night food has looked at. Knowing that people are snacking within that hour or two before bed, what should we be putting in our bodies and what shouldn't we be putting in our bodies to make sure that we get the best night of sleep and sleep is becoming more and more of a challenge for a lot of people, uh, especially now with COVID.

So we think the timing is great, and we think there's a billion dollar category to be had here in the category of nighttime. So is this something, I guess that took a lot of, you know, scientific research on, on night foods and to figure out like what it is specifically about, um, you know, what's in typical ice cream that can disrupt someone's.

Well, I mean, there's been a general consensus for quite some time, and there's been a lot of research over the years. Uh, you know, excess sugar, uh, fat and calories are problematic. Um, you know, there are certain nutrients that can be beneficial, magnesium, calcium, zinc, vitamin B6. Uh, so the research really existed.

Uh, and when we launched our, our challenge was. You know, to formulate a great tasting product, uh, with all these ingredients that can satisfy those cravings in that way. So, uh, really we stood on the shoulders of the existing research, which was out there. And it's really interesting because with so much snacking already happening at night.

See, this is, this is not a behavior. That's, uh, it's not a trend. It's not a fad. This is how humans are wired. We're wired to crave these things at night, so it's not going away. So there was a lot of talk and a lot of research before we launched, but nobody had ever launched a product into the category, which we thought was really interesting.

Now we've got Nestle, we've got Unilever, we've got Pepsi. They're all talking publicly about this category. Um, but, but we're the only ones operating in it. And so the challenge for us was not really to figure out what our snacks should be. An ice cream is the first, you know, what they should contain. It's more about really educating